Purpose: Vitamin D de ciency or insu ciency plays a role in the initiation and perpetuation of certain autoimmune diseases. e purpose of this study was to measure the vitamin D status of children with Familial Mediterranean Fever (FMF) and compare it to their healthy peers.
Familial Mediterranean Fever (FMF) is an autosomal recessive autoin ammatory disease characterized by recurrent selflimiting attacks of fever and serosal in ammation [1] . FMF predominantly a ects Turks, Arabs, Jews and Armenians [2, 3] . e relevant gene, Mediterranean fever (MEFV), is located on chromosome 16 and encodes a protein, pyrin/marenostrin, that plays a role in the suppression of in ammatory pathways [4] [5] [6] . Upon mutation of the MEFV gene, production of interleukin (IL)-1β and tumor necrosis factor (TNF)-α increase, stimulating the innate immune response [6] [7] [8] . Vitamin D is one member of a group of steroids (secosteroids). Secosteroids are not considered true vitamins because adequate exposure to sunlight (speci cally, ultraviolet-B light) eliminates the need for dietary vitamin D supplementation (which typically supplies only 20% of the required daily amount of the compound) [9] .
Vitamin D is involved in phosphate-calcium homeostasis and bone formation and resorption [10] . It plays pivotal roles in the regulation of cell proliferation and di erentiation and in cytokine production [11, 12] . Indeed, vitamin D de ciency/ insu ciency is associated with poor development, a higher prevalence of various malignancies (colorectal, uterine, prostate and skin), development of chronic diseases (osteoporosis and in ammatory bowel disease) and development of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus [SLE] , multiple sclerosis and type I diabetes mellitus) [13] [14] [15] [16] [17] .
Of relevant prior studies, only two studied serum vitamin D levels in adult FMF patients [18, 19] . us, we explored whether FMF children exhibit hypovitaminosis D compared with healthy peers.
Materials and Methods
A total of 132 pediatric FMF patients were treated in our outpatient clinic. Twenty patients were too old for inclusion in the study (> 19 years of age). Of the remaining 112 FMF patients, 50 agreed to participate in the study. Serum vitamin D levels were measured via HPLC in all 50 patients admitted for follow-up examinations during the period from July to September 2012. Fi y healthy age-and gender-matched children, who visited our outpatient clinic for routine checkups, were recruited as control subjects but one later withdrew from the study.
e study was approved by the Gaziosmanpasa University Clinical Research Ethics Committee. All procedures were conducted as dictated by the Declaration of Helsinki a er written informed consent was obtained from patients and/or guardians.
Blood samples were drawn for routine testing and 25(-OH) vitamin D levels were measured in residual samples using a Shimadzu HPLC system (Shimadzu Corporation, Kyoto, Japan) with the aid of a 25(-OH) Vitamin D3 kit (RECIPE Chemicals+Instruments GmbH, Munich, Germany).
Subjects were screened for the presence of all 12 known FMF mutations. Genomic DNA was extracted from 5 mL amounts of whole blood obtained via standard procedures. FMF mutations were detected using a reverse-hybridization test strip-based assay ( No patient or control was taking any other drug (anticoagulant, anticonvulsant or growth hormone), vitamin, or medicinal plant material or supplement that could a ect vitamin D levels. All blood samples were drawn over the same period ( July September 2012). Plasma 25(-OH) vitamin D3 levels less than 30 and 10 µg/L were considered to indicate vitamin D insu ciency and de ciency, respectively [21, 22] .
FMF disease severity scores were calculated with reference to age at disease onset, number of attacks per month, amyloidosis status, arthritis status, colchicine dose and the presence or absence of erysipelas-like erythema. Scores of 3-5 were considered to re ect mild disease, 6-8 moderate disease, and ≥ 9 severe disease [23] . Demographic data, information on disease duration and current colchicine dose were retrieved from our hospital database or collected during interviews of patients.
Statistical analysis was performed using SPSS version 19 (IBM SPSS, Somers, NY, USA). Continuous variables are presented as means ± standard deviations and categorical variables are presented as counts with percentages. Di erences in categorical variables were compared using the chi-squared test. e Kolmogorov-Smirnov test was used to evaluate whether the distribution of variables was normal. One-way analysis of variance (ANOVA) and Kruskal-Wallis analysis of variance were used to compare continuous data that were normally and nonnormally distributed, respectively. e unpaired t-test was used to compare the means of normally distributed variables. Multivariate logistic regression was used to explore the e ects of Vitamin D de ciency and insu ciency were evident in 26% and 62% of FMF patients, respectively (Table 3 ) and the proportions of subjects with vitamin D de ciency and insuciency was higher in FMF patients than controls (p<0.05). Lower vitamin D levels were evident in female FMF patients (p<0.05) whereas no between-gender di erence was evident in controls (p>0.05). Plasma vitamin D3 levels were similar in patients, despitedi erent FMF symptom severity scores (p>0.05; Figure 1) .
No correlations were evident among vitamin D3 status and allelic status (homozygous or heterozygous), presence of the M694V mutation (on one or both chromosomes) and disease severity score (Table 4) . Table 5 lists the signi cant outcomes of multivariable logistic regression analysis of vitamin D3 status. is analysis included the variables listed in Table 4 : allelic status, presence of the M694V mutation and disease severity score. e latter three variables did not in uence vitamin D3 status. 
Discussion
is is the rst study to show that plasma vitamin D3 levels are lower in FMF children than in age-and gender-matched healthy controls.
T helper cells play a crucial role in FMF pathogenesis and many other autoimmune and autoin ammatory diseases [13] [14] [15] [16] [17] . T helper 1 cells produce IFN-γ and TNF-β. Aypar et al. [24] showed that the IFN-γ levels produced by 1 cells were signi cantly higher than those of healthy controls during FMF attacks, indicating that 1 polarization triggered in ammation. Koklu et al. [25] reported high IFN-γ levels in FMF patients during both attack and remission periods.
Recently, the vitamin D receptor (VDR) has been shown to be expressed by cells of the immune system, upon which vitamin D exerts immunomodulatory e ects [11, 12, 26, 27] . Vitamin D inhibits the di erentiation and maturation of both myeloid cells 11 and pathogenic proin ammatory T cells including 1 and 17 cells [9, 26, 28] . It also inhibits the production of IL-6 and INF-γ [29, 30] . us, low vitamin D levels might activate the in ammatory networks of FMF patients, triggering attacks.
FMF is an episodic disease featuring in ammatory attacks, but subclinical in ammation is also present during attack-free periods and many a ect clinical outcomes via a pathophysiological process that remains poorly understood [1, 31] . As vitamin D has immunomodulatory e ects on cells and a ects cytokine production, it is possible that the low vitamin D levels of FMF patients may explain the presence of subclinical inammation. Vitamin D de ciency is evident in many patients treated by rheumatologists; therefore, FMF patients were tested to see if they were similarly de cient. ree studies from Turkey reported low vitamin D levels in adult and child FMF patients [18, 19, 32] . Our results are in agreement with these data.
Although some studies have described relationships between low vitamin D levels and the severity of various rheumatological and autoimmune diseases, others have reported no association between vitamin D levels and the extent of disease activity in adult SLE patients [33] [34] [35] [36] [37] and Anik et al. [32] found no signi cant correlation between vitamin D levels and disease severity scores in FMF children from Turkey. In the present study, no correlation was found between FMF symptom severity score and vitamin D level; however, all FMF patients, whether they had mild, moderate or severe symptom scores, had low vitamin D levels. Such contradictory ndings may be explained by the fact that our patient numbers were small and VDR genetic polymorphism was evident. VDR gene polymorphism may be responsible for various disease activities [22, 37] . We will study genetic polymorphisms further in the context of FMF.
A recent study performed in western Turkey found that vitamin D levels in FMF children were inversely correlated with the cumulative colchicine dose [32] It was concluded that [32, 38] . Another reason why vitamin D3 levels were low in FMF patients receiving colchicine may be that the drug triggers malabsorption by, and other adverse events in, the gastrointestinal system. Colchicine may decrease serum vitamin B12 levels by a ecting the function of the intestinal mucosa [39, 40] . Although malabsorption of Vitamin B12 has been proposed, no study has yet investigated the e ects of colchicine on vitamin D absorption.
Several factors including season, age, exposure to sunlight, use of certain medications, traditions, dress habits and geographical location in uence vitamin D metabolism [18, 19, 41] . Vitamin D levels are higher in summer and autumn because of increased exposure to sunlight [42, 43] . Although the present study was conducted between July and September 2012, vitamin D levels were low in patients but normal in controls; thus, seasonality cannot explain this di erence.
Our study had certain limitations. First, vitamin D levels were determined in only about one-third of 132 FMF patients admitted to our clinic. Second, no information on dietary calcium or vitamin D intake, dress habits, exposure to the sun, or exercise habits was collected, and so the e ects of such factors on plasma vitamin D levels could not be evaluated.
In conclusion, vitamin D de ciency is frequent in children with FMF. It remains unclear whether low-level vitamin D3 status triggers FMF attacks or whether a lower vitamin D3 level is an unwanted side-e ect of colchicine treatment. It would be useful to explore the possible relationship between vitamin D de ciency and the numbers of FMF attacks and disease severity scores in large FMF cohorts, and to evaluate the possible bene cial e ects of vitamin D supplementation.
